Thromb Haemost 1992; 68(06): 634-636
DOI: 10.1055/s-0038-1646334
Original Article
Schattauer GmbH Stuttgart

Treatment of Venous Thromboembolism in Patients with Congenital Deficiency of Antithrombin III

S Schulman
The Dept of Internal Medicine, Karolinska Hospital, Stockholm and Dept of Medicine II, Sahlgren’s Hospital, Gothenburg, Sweden
,
L Tengborn
The Dept of Internal Medicine, Karolinska Hospital, Stockholm and Dept of Medicine II, Sahlgren’s Hospital, Gothenburg, Sweden
› Author Affiliations
Further Information

Publication History

Received 27 March 1992

Accepted after revision 31 July 1992

Publication Date:
04 July 2018 (online)

Preview

Summary

The treatment course of all thromboembolic events in the patients with congenital deficiency of antithrombin III (AT III) in the national Swedish register was reviewed in order to assess the appropriate medical therapy in this situation. The medical treatment of 70 events of venous thromboembolism was evaluated. There were eight cases with signs of clinical progression. The risk of therapeutic failure with heparin could be as low as 1.5% or as high as 9.2%. It would not be cost-effective to substitute with concentrates of AT III in every case with congenital deficiency thereof in connection with acute venous thromboembolism. “Heparin resistance” does not seem to be a problem in the vast majority of these patients.